The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...

A deal announced Monday will see the U.K. temporarily sidestep levies on Britain-originated drugs by loosening rules that ...

The results position Belite, one of the sector’s top-performing companies since 2022, to seek approval of what could be the ...

Indiana shows high potential for the state to become the premiere destination to research, commercialize, scale biotechnology ...

The startup’s lead prospect stabilizes abnormal proteins in patients with amyloid “light chain” amyloidosis, an approach that ...